These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Fibroblast growth factor-23 and cardiovascular events in CKD. Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M; J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986 [TBL] [Abstract][Full Text] [Related]
23. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Jamal SA; West SL; Nickolas TL Osteoporos Int; 2014 Jan; 25(1):71-6. PubMed ID: 24114399 [TBL] [Abstract][Full Text] [Related]
24. Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Iwasaki Y; Kazama JJ; Yamato H; Shimoda H; Fukagawa M Bone; 2013 Dec; 57(2):477-83. PubMed ID: 23920356 [TBL] [Abstract][Full Text] [Related]
25. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Tanaka H; Iwasaki Y; Yamato H; Mori Y; Komaba H; Watanabe H; Maruyama T; Fukagawa M Bone; 2013 Oct; 56(2):347-54. PubMed ID: 23851293 [TBL] [Abstract][Full Text] [Related]
26. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Fukagawa M; Yokoyama K; Koiwa F; Taniguchi M; Shoji T; Kazama JJ; Komaba H; Ando R; Kakuta T; Fujii H; Nakayama M; Shibagaki Y; Fukumoto S; Fujii N; Hattori M; Ashida A; Iseki K; Shigematsu T; Tsukamoto Y; Tsubakihara Y; Tomo T; Hirakata H; Akizawa T; ; Ther Apher Dial; 2013 Jun; 17(3):247-88. PubMed ID: 23735142 [No Abstract] [Full Text] [Related]
27. Increased risk of hip fracture among Japanese hemodialysis patients. Wakasugi M; Kazama JJ; Taniguchi M; Wada A; Iseki K; Tsubakihara Y; Narita I J Bone Miner Metab; 2013 May; 31(3):315-21. PubMed ID: 23292163 [TBL] [Abstract][Full Text] [Related]
28. The role of FGF23 in CKD--with or without Klotho. Komaba H; Fukagawa M Nat Rev Nephrol; 2012 Jun; 8(8):484-90. PubMed ID: 22714041 [TBL] [Abstract][Full Text] [Related]
29. FGF23 induces left ventricular hypertrophy. Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788 [TBL] [Abstract][Full Text] [Related]
30. Diseases of the parathyroid gland in chronic kidney disease. Komaba H; Kakuta T; Fukagawa M Clin Exp Nephrol; 2011 Dec; 15(6):797-809. PubMed ID: 21818548 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Iimori S; Mori Y; Akita W; Kuyama T; Takada S; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y Nephrol Dial Transplant; 2012 Jan; 27(1):345-51. PubMed ID: 21652550 [TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978 [TBL] [Abstract][Full Text] [Related]
33. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group Kidney Int Suppl; 2009 Aug; (113):S1-130. PubMed ID: 19644521 [TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutiérrez OM; Mannstadt M; Isakova T; Rauh-Hain JA; Tamez H; Shah A; Smith K; Lee H; Thadhani R; Jüppner H; Wolf M N Engl J Med; 2008 Aug; 359(6):584-92. PubMed ID: 18687639 [TBL] [Abstract][Full Text] [Related]
35. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. London GM; Marchais SJ; Guérin AP; Boutouyrie P; Métivier F; de Vernejoul MC J Am Soc Nephrol; 2008 Sep; 19(9):1827-35. PubMed ID: 18480316 [TBL] [Abstract][Full Text] [Related]
36. FRAX and the assessment of fracture probability in men and women from the UK. Kanis JA; Johnell O; Oden A; Johansson H; McCloskey E Osteoporos Int; 2008 Apr; 19(4):385-97. PubMed ID: 18292978 [TBL] [Abstract][Full Text] [Related]
37. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Fujiwara S; Nakamura T; Orimo H; Hosoi T; Gorai I; Oden A; Johansson H; Kanis JA Osteoporos Int; 2008 Apr; 19(4):429-35. PubMed ID: 18292977 [TBL] [Abstract][Full Text] [Related]
38. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Nii-Kono T; Iwasaki Y; Uchida M; Fujieda A; Hosokawa A; Motojima M; Yamato H; Kurokawa K; Fukagawa M Kidney Int; 2007 Apr; 71(8):738-43. PubMed ID: 17264878 [TBL] [Abstract][Full Text] [Related]
39. The kidney and bone metabolism: Nephrologists' point of view. Fukagawa M; Hamada Y; Nakanishi S; Tanaka M J Bone Miner Metab; 2006; 24(6):434-8. PubMed ID: 17072734 [TBL] [Abstract][Full Text] [Related]
40. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Jadoul M; Albert JM; Akiba T; Akizawa T; Arab L; Bragg-Gresham JL; Mason N; Prutz KG; Young EW; Pisoni RL Kidney Int; 2006 Oct; 70(7):1358-66. PubMed ID: 16929251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]